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Resolution Pharmacology identifies drugs developed on the biology of the resolution
phase of inflammation, the complex molecular and cellular network of events that ensure
the tight temporal and spatial control on the inflammatory response. As such, new
anti-inflammatory and pro-resolving drugs could derive from pro-resolving mediators
and receptors. To implement faithful screening programs, however, it is important to
rely on predictive signaling pathway relevant for the ultimate bio-action of interest.
Herein we performed an analysis with four prototypical melanocortin receptor (MC1,3,4,5)
agonists. The choice fell on the natural agonist αMSH, the small molecule BMS-
470539, and the synthetic derivatives [D-Trp8]-γMSH and [Nle4,D-Phe7]-αMSH. We
used human macrophages and quantified the effect of the four agonists on inhibition
of cytokine release and promotion of efferocytosis. All agonists (1–10 µM) significantly
inhibited cytokine release by LPS-stimulated cells whereas [D-Trp8]-γMSH was the most
effective in inducing efferocytosis (∼60% increase). To study the signaling profile, we
monitored cAMP accumulation and ERK1/2 phosphorylation, and constructed biased
plots that revealed a marked biased profile of [D-Trp8]-γMSH toward phospho-ERK1/2.
Correlation matrix analysis of all data pointed at phospho-ERK1/2 at any receptor as
the most prominent pathway to attain pro-phagocytic actions, and MC1 receptor as the
most relevant to drive anti-cytokine effects. In conclusion, the present study highlights
the need to associate single-target signaling data with relevant functional outcomes.
In this manner, we would increase our chances to optimize drug discovery programs
during the early target validation and hit-to-lead phases.
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INTRODUCTION
The study of the resolution of inflammation as a specific feature of the whole inflammatory response
was formally established one decade ago (Serhan et al., 2007), when the therapeutic potential of
mimicking the way our own body terminates inflammation was envisaged. Since then, multiple
pro-resolving molecular mediators have been discovered and the cellular mechanisms involved in
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the active termination of the inflammatory response defined
(Ortega-Gomez et al., 2013). The field is now entering a new
stage in which this new knowledge is being translated into
novel drugs -many entering clinical development phase-, and
drug discovery programs are being designed with the resolution
approach in mind (Perretti et al., 2015). The melanocortin
system (MC) constitutes one of such endogenous pro-resolving
mechanisms, in addition to its multiple roles including
energy homeostasis, skin pigmentation or steroidogenesis,
thus presenting very diverse potential therapeutic applications
(Leone et al., 2013; Montero-Melendez, 2015; Ferrante et al.,
2016, 2017). However, the development of the “ideal” MC
molecule is a proven challenge. Ideally, besides parameters
such as potency or stability, an MC drug should also present
receptor selectivity according to the intended indication. In
addition, regarding the receptor activation profile induced
by the drug, we still do not know what represents an
ideal MC drug. For example, as cAMP activation is known
to be essential for melanin production in melanocytes, it
is unknown whether other functional outcomes (e.g., anti-
inflammatory actions) require the same activation profile.
The recent discovery of the existence of ligand bias at
MC receptors (Buch et al., 2009; Montero-Melendez et al.,
2015; Yang and Tao, 2017) suggests that in-depth studies
on the relation between the signaling pathways activated
by MCRs and functional outcomes should be conducted,
as a better definition of this functional selectivity may
lead to better drugs with improved safety and efficacy
profiles.
In this Brief Report we used human monocyte-derived
macrophages and present an association analysis between
melanocortin functional outcomes and signaling pathways
engaged by the four prototypical agonists, widely used
compounds in melanocortin research. We propose that this




The following drugs were used: αMSH, BMS-470539 (BMS),
[Nle4,D-Phe7]-αMSH (NDP), and [D-Trp8]-γMSH (DTrp)
(Tocris); M-CSF (PeproTech); LPS E. coli O111:B4 (Sigma).
Isolation of Human Primary Cells
Experiments using healthy volunteers (written consent provided)
were approved by P/00/029 East London and The City
Local Research Ethics Committee 1. Blood was collected
into 3.2% sodium citrate, diluted 1:1 with RPMI-1640 and
separated through a double-density gradient using Histopaque
1077/1119 (Sigma-Aldrich). PBMCs were collected from the
top layer and differentiated into macrophages in complete
media + 50 ng/ml M-CSF during 7 days. Neutrophils were
collected from the middle layer and incubated in 10% FCS
overnight at 37◦C, 5% CO2 to let neutrophils undergo
spontaneous apoptosis.
Stimulation of Differentiated Primary
Macrophages
Differentiated macrophages were stimulated with 1 ng/ml LPS,
30 min post drug treatments. Supernatants were collected 18 h
later and analyzed by ELISA. Melanocortin drugs concentrations
were chosen according to previous reports (Montero-Melendez
et al., 2011).
Cell Transfections
HEK293A cells were maintained in DMEM containing 10%
FCS and 1% penicillin/streptomycin and kept at 37◦C with
5% CO2. Cells were transfected with MC1R, MC3R, MC4R or
MC5R TrueORF cDNA clones (Origene) using Lipofectamine
2000 (Invitrogen) and OptiMEM according to manufacturer’s
instructions and used after 24 h.
Gene Expression
Ribonucleic acid (RNA) was extracted using PureLink RNA
Mini Kit with DNase I digestion (Thermo Scientific). cDNA
was synthesized (1 µg RNA) with SuperScript VILO MasterMix
(Invitrogen). End-point PCR was performed with ReddyMix
PCR Master Mix (Thermo Scientific) and amplified products
visualized by 3% agarose electrophoresis. To account for
genomic DNA contamination, negative cDNA controls (i.e.,
without reverse transcriptase) were used. Quantitect primers
(QIAGEN/amplicon size) used are the following: MC1R
(QT01004241/137bp), MC2R (QT01155007/118bp), MC3R
(QT00209895/74bp), MC4R (QT00245595/89bp), MC5R
(QT00211960/146bp), POMC (QT00001204/126bp), PCSK1
(QT00013853/139bp), PCSK2 (QT00054754/126bp), MRAP
(QT00103866/86bp), MRAP2 (QT00493150/113bp), GAPDH
(QT00079247/95bp), and HPRT1 (QT00059066/130bp).
ELISA and EIA Assays
The following kits were used following manufacturer’s
instructions: cAMP Select EIA kit (Cayman Chemical); ERK1/2
(pT202/Y204) SimpleStep ELISA Kit (Abcam); CCL-2, IL-6,
IL-10, and IL-8 Ready-SET-Go ELISA (eBioscience).
Efferocytosis Assay
Differentiated macrophages were stimulated with compounds/
vehicle for 30 min before the addition of apoptotic neutrophils
(1:5 macrophage to neutrophil ratio) for 1 h. Cells were fixed
and stained using the myeloperoxidase (MPO) assay by adding
0.1 mg/ml of dimethoxybenzidine (Sigma-Aldrich) and 0.03%
(v/v) hydrogen peroxide for 1 h. Cells were analyzed by light
microscopy with three random fields being acquired per well.
Clearance Index: (%Phagocytosis× %Multiple ingestions)/100.
Statistical Analysis
Statistical parameters including the exact value of n for each
experiment, nature of data shown (mean ± SE) and statistical
significance are reported in Figure Legends. Data is judged to
be statistically significant when p < 0.05. Statistical analysis was
performed in GraphPad PRISM v7.
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RESULTS
Melanocortin Pathway Expression in
Primary Human Macrophages
Expression profile analyses by qPCR (Figure 1A) indicated
presence of the gene products for the receptors MC1R, MC3R,
MC4R, and MC5R. The processing enzyme PCSK1 and the
accessory proteins melanocortin-2 receptor accessory protein 1
and 2 (MRAP, MRAP2) were also expressed. The expression of
POMC gene was donor-dependent as it was detected in 25%
of donors tested (n = 4). Taken together, human macrophages
express multiple members of the MC pathway.
Melanocortin Agonists Reduce
LPS-Induced Macrophage Activation
The ability of melanocortin ligands to reduce cytokine release by
macrophages challenged with inflammatory stimuli was studied
using: αMSH (natural peptide, pan-agonist), BMS-470539 (BMS,
synthetic small molecule, MC1 selective), [D-Trp8]-γMSH
(DTrp, synthetic peptide, preference for MC3 over the other
receptors) and [Nle4,D-Phe7]-αMSH (NDP, synthetic stable
peptide, pan-agonist). LPS stimulation induced a marked
increase in the release of CCL-2, IL-6, IL-10, and IL-8.
All compounds reduced LPS-dependent cytokine release in
a concentration-dependent manner (Figure 1B). Efficacy was
lower for the natural agonist αMSH compared to the synthetic
ones. The highest efficacy was observed for NDP achieving
complete abrogation of IL-6 release at 10 µM.
Pro-resolving Actions of Melanocortin
Agonists
We next investigated the pro-resolving actions of these molecules
by assessing promotion of efferocytosis, a key resolution
mechanism that promotes the non-phlogistic clearance of
dead cells after the inflammatory acute phase. All compounds
augmented efferocytosis of human apoptotic neutrophils by
primary macrophages (statistically significant for DTrp), as
compared with non-treated (ctrl) cells (Figure 1C). We also
quantified multiple ingestions, as they reflect the effectiveness
of dead cells clearance (i.e., whether they also “eat” more).
DTrp induced a 57% increase in the number of macrophages
performing multiple ingestions. Together, the clearance index
showed increased effectiveness in apoptotic cell clearance for all
compounds.
Existence of Ligand Bias on
Melanocortin Receptor Activation
cAMP activation by melanocortin drugs has been extensively
studied while ERK1/2 activation is much less explored. We
confirm the MC drugs used in this report can induce ERK1/2
phosphorylation in primary human macrophages (∼15–40%
increase at 2 µM after 5 min stimulation – data not shown).
In our next approach, we linked biological properties to cell
signaling, generating concentration response curves for both
cAMP accumulation and ERK1/2 phosphorylation using HEK-
293 cells transfected with each single receptor under investigation
(Figure 2A). Bias plots were then constructed by representing
one pathway against the other (Figure 2B). Ligand bias was
analyzed in reference to the endogenous αMSH, i.e., considering
the response induced by αMSH as the reference, and as such
any deviation from that would indicate existence of biased
signaling. Interestingly, DTrp presented preference for ERK1/2
phosphorylation over cAMP engagement at all the MCRs. BMS
showed a similar trend, with a clear shift toward phospho-
ERK1/2 compared to αMSH on MC1. On the other receptors, the
preference of BMS for phospho-ERK1/2 was more evident given
its partial agonistic activity (although with very low potency)
on MC3−5, while no significant activity was attained on the
cAMP pathway. This effect of BMS (reported as an MC1-selective
drug) is of particular relevance, as it highlights the importance of
measuring signaling outcomes other than the canonical cAMP to
confidently attribute receptor selectivity to a molecule. To a lesser
extent, the αMSH derived peptide NDP also presents some degree
of ligand bias toward phospho-ERK1/2 at MC1 and MC3.
Association of Melanocortin Distinct
Signaling Profiles With Functional
Outcomes
To determine whether bias signaling patterns lead to functional
consequences we generated a correlation matrix compiling all the
data produced in this study at 10 µM: efficacy at either signaling
pathway, cytokine reduction and increase in efferocytosis. We
could then highlight several associations that may help elucidate
the contribution of each receptor type and signaling pathways
to functional outcomes (Figure 2C). For example, the only
receptor positively associated with both reduction in cytokines
and increased phagocytosis was MC1 (highlighted in magenta).
Moreover, this positive association was only found with phospho-
ERK1/2-MC1, while the association with cAMP-MC1 was indeed
the opposite. Strikingly, cAMP pathway at all receptors was
negatively associated with cytokine reduction (highlighted in
purple). The case of IL-6 showed, however, a different trend, with
positive (although weak) association with phospho-ERK1/2 and
cAMP at both MC3 and MC4 (highlighted in green). The analysis
of phagocytosis also revealed new clues about the relevant
signaling that may drive this effect. In addition to phospho-
ERK1/2 at MC1, as mentioned earlier, ERK1/2 phosphorylation at
all other receptors was also positively and strongly associated with
increase in efferocytosis and multiple ingestions (highlighted in
blue). This is in agreement with the high pro-phagocytic effect
obtained with DTrp shown previously on Figure 1C, and the
biased signaling that this receptor presents toward phospho-
ERK1/2, as shown in Figure 2B.
DISCUSSION
G-protein coupled receptor (GPCRs) activation is a highly
dynamic process where receptor proteins can acquire multiple
active states evoking distinct signaling pathways (Kroeze
et al., 2003). The complex pharmacology of these receptors
is determined by properties like ligand promiscuity, temporal
pathways network activation, desensitization, ligand independent
Frontiers in Pharmacology | www.frontiersin.org 3 August 2018 | Volume 9 | Article 919
fphar-09-00919 August 11, 2018 Time: 17:24 # 4
Patruno et al. Identification of Signaling Bias at Melanocortin Receptors
FIGURE 1 | Effects of melanocortin drugs on macrophage function. (A) Expression of members of the MC pathway by PCR. Two representative donors are shown.
Lack of amplification from genomic DNA is reported in the last line. (B) Macrophages were stimulated with LPS (1 ng/ml) 30 min after the addition of melanocortin
drugs at the indicated concentrations. Supernatants were collected after 18 h and cytokines measured by specific ELISA. (C) Macrophages were treated with the
indicated melanocortin drugs (10 µM) for 30 min prior to the addition of apoptotic neutrophils. The MPO assay was performed 1 h later to specifically stain ingested
neutrophils. Phagocytosis was calculated as % of macrophages containing at least one neutrophil inside. Multiple ingestions were quantified as % of phagocytic
macrophages that ingested more than 1 neutrophil. Clearance Index = (%phagocytosis × %multiple ingestions)/100. Values for basal (ctrl) phagocytosis and multiple
ingestions were 27 and 15%, respectively. Photograph shows the dark brown coloration selectively acquired by neutrophils after performing the MPO assay. Data
represent mean ± SEM of 3 independent human donors and were analyzed by repeated measures one-way ANOVA (p values shown in graphs) followed by Dunn’s
multiple comparison test (∗p < 0.05, ∗∗p < 0.01).
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FIGURE 2 | Association between signaling cascades and functional effects of melanocortin drugs on macrophages. (A) Concentration dependent accumulation of
cAMP and formation of ERK1/2 phosphorylation (p-ERK1/2) upon melanocortin stimulation of transiently transfected cells. Data represent mean ± SEM of n = 2–3
independent experiments, each one in duplicate. (B) Bias plots for each MC receptor were constructed using equimolar concentrations (using full response curves
10 µM–0.13 nM) at the two pathways cAMP (pg/ml) and p-ERK1/2 (arbitrary units, AU), presenting one variable as a function of the other. Arrows indicate biased
signaling respect to the natural agonist αMSH. (C) A correlation analysis was performed using all data generated in the present study using values for 10 µM: cAMP
(pg/ml) and ERK1/2 phosphorylation (AU), reduction of cytokines release (%) and increase on phagocytosis and multiple ingestions (%), all shown in the insert. The
analysis was performed by Pearson correlation test. Strength of the association is denoted by both color and size of bubble (darker color and bigger size meaning
higher correlation; red, negative; blue positive). Bar indicates correlation coefficient “r” ranging from r = –1 (negative correlation) to r = 1 (positive correlation). White
asterisks indicate statistically significant association (∗p < 0.05).
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activation, allosteric modulation or ligand bias (Melancon et al.,
2012; Kenakin and Christopoulos, 2013; Montero-Melendez
et al., 2017; Sexton and Christopoulos, 2018), presenting an
arduous challenge, yet a unique opportunity, for innovative drug
discovery. The exploitation of the full potential of these receptors,
like MCRs, requires a better understanding of their behavior and
discarding the old view of GPCRs as a plain linear sequence of
events of “ligand-receptor-pathway-effect.”
Here we performed a systematic analysis selecting two
major biological actions of MCR agonists and studied their
association (positive or negative) with two signaling readouts.
Since we used four distinct prototypical agonists at these
receptors (all of them expressed in human macrophages),
combining natural with synthetic compounds, peptides with
small molecules, the study is in itself novel and may pave
the way to a “bio-matrix” based approach relevant for drug
discovery programs. In fact, our findings represent a challenge
against the current dogma on cAMP drug discovery approaches,
assuming cAMP as the major, or even the only pathway used
to inform candidate selection. Surprisingly, cAMP pathway at
all receptors was markedly negatively associated with the ability
to reduce cytokine release, while ERK1/2 phosphorylation at
MC1 and MC3,4,5 were positively associated with desirable
effects on cytokine release and promotion of phagocytosis,
suggesting a mayor role for this non-canonical pathway
in the pro-resolving and anti-inflammatory actions of MC
drugs. This confirms our recent discovery of an ERK1/2-
biased melanocortin small molecule (AP1189) that presents
anti-inflammatory actions despite no induction of cAMP
(Montero-Melendez et al., 2015). In fact, the ERK1/2 inhibitor
FR180204 completely abrogated the pro-efferocytic effect of
AP1189. Currently, all drug screening programs on MC drug
discovery are based on cAMP accumulation, despite the lack
of consistent evidence that this pathway is indeed the most
therapeutically relevant one, at least to develop new anti-
inflammatory agents. Thus, this promising candidate (currently
on phase I trial–CT#2016-004171-48-) would have been filtered
out in a typical cAMP-based screening. This analysis also
revealed interesting differences between cytokine reduction and
promotion of phagocytosis, where the latter seems to be strongly
dependent on ERK1/2 phosphorylation at MC3,4,5 rather than
MC1.
Correlation analyses need to be interpreted considering that
association does not imply causation. Therefore, more in-
depth analyses are necessary to fully understand associations
between receptors-pathways-functions to inform drug discovery
programs to prevent decisions based on assumptions. Here,
we propose that a “bio-matrix” based approach would enable
a better compound profiling, facilitating candidate selection
for follow up development while, at the same time, ensuring
the relevant biological properties are taken into consideration
early-on to inform this selection. Furthermore, macrophages
express multiple melanocortin receptors which are activated
simultaneously by a given agonist. However, drug discovery
screenings are usually performed on a single target basis using
transfected cell as we did here. Our study then highlights the
relevance of understanding single-target signaling data and its
association with “real-cells” functional outcomes to better define
the relevant parameters to optimize drug discovery programs
during early target validation and hit-to-lead phases.
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